The Food and Drug Administration has approved the first diagnostic test for cancer-causing mutations in multiple genes at one time in many types of cancer that will help inform treatment options. For patients with lung cancer this means that fewer tests are necessary to determine what drugs are best to treat their specific lung cancer.
At the same time, the Center for Medicare & Medicaid Services (CMS) released a Draft Coverage Decision under a new ‘Parallel Review Program’ to cover this test for patients with advanced cancer. CMS is likely to cover these tests in the near future for some patients with Medicare.
This newly approved test is one part of the molecular testing offered through LCA’s LungMATCH program. To learn more about molecular testing and how it can affect your treatment decisions, please contact our HelpLine at 1-800-298-2436 and email email@example.com.